Header Logo

Connection

FRANK E. MOTT to Cholangiocarcinoma

Back to Details
This is a "connection" page, showing publications FRANK E. MOTT has written about Cholangiocarcinoma.
FRANK E. MOTT
Connection Strength
0.166
Cholangiocarcinoma
  1. First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors. Oncologist. 2024 Apr 04; 29(4):e514-e525.
    View in: PubMed
    Score: 0.166
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.